• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Travere Therapeutics Inc (NQ: TVTX )

    13.99 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,786,285
    Open 13.74
    Bid (Size) 13.15 (10)
    Ask (Size) 15.59 (1)
    Prev. Close 13.99
    Today's Range 13.40 - 14.21
    52wk Range 5.120 - 15.36
    Shares Outstanding 60,717,176
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Where Travere Therapeutics Stands With Analysts
    Via Benzinga
    Micron To $150? Here Are 10 Top Analyst Forecasts For Friday
    Via Benzinga

    Performance

    YTD
    +46.34%
    +46.34%
    1 Month
    +45.73%
    +45.73%
    3 Month
    +72.93%
    +72.93%
    6 Month
    +98.72%
    +98.72%
    1 Year
    +66.15%
    +66.15%

    More News

    Read More
    Costco, Scholastic And 3 Stocks To Watch Heading Into Friday
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's After-Market Session
    Via Benzinga
    Travere Therapeutics Announces Voluntary Pause of Enrollment in the Phase 3 HARMONY Study of Pegtibatinase Related to Commercial Manufacturing Scale-Up
    From Travere Therapeutics, Inc.
    Via GlobeNewswire
    Analyst Ratings For Travere Therapeutics
    Via Benzinga
    Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Travere Therapeutics, Inc.
    Via GlobeNewswire
    Travere Therapeutics to Present at the 2024 Cantor Global Healthcare Conference
    From Travere Therapeutics, Inc.
    Via GlobeNewswire
    This United States Steel Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
    Via Benzinga
    Quanex Building Products Posts Better-Than-Expected Results, Joins Zumiez, Guidewire Software, Smartsheet And Other Big Stocks Moving Higher On Friday
    Via Benzinga
    Expert Ratings For Travere Therapeutics
    Via Benzinga
    Travere Stock Pops After Snagging Full Approval For Calliditas Rival In Kidney Disease
    Via Investor's Business Daily
    NIO To Rally Around 65%? Here Are 10 Top Analyst Forecasts For Friday
    Via Benzinga
    Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy
    From Travere Therapeutics, Inc.
    Via GlobeNewswire
    Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2024
    From Travere Therapeutics, Inc.
    Via GlobeNewswire
    Travere Therapeutics to Present at Upcoming Investor Conferences
    From Travere Therapeutics, Inc.
    Via GlobeNewswire
    CS Diagnostics (OTC: FZRO) Acquisitions Announced, Landmark Agreement Signed, Moving Forward Through 2024
    Via AB Newswire
    Topics Intellectual Property
    Exposures Intellectual Property
    Travere Therapeutics Reports Second Quarter 2024 Financial Results
    From Travere Therapeutics, Inc.
    Via GlobeNewswire
    Week In Review: Nanjing Triastek Partners With BioNTech In A $1.2 Billion Drug Development Deal
    Via Talk Markets
    Travere Therapeutics to Report Second Quarter 2024 Financial Results
    From Travere Therapeutics, Inc.
    Via GlobeNewswire
    10 Health Care Stocks Whale Activity In Today's Session
    Via Benzinga
    Nvidia, Micron, Arlo Technologies And Other Big Stocks Moving Higher On Tuesday
    Via Benzinga
    Travere Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference
    From Travere Therapeutics, Inc.
    Via GlobeNewswire
    Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Travere Therapeutics, Inc.
    Via GlobeNewswire
    Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Travere Therapeutics, Inc.
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.